Abacus Diagnostica, Kaivogen and Labrox joining forces to form a global diagnostics pioneer – Enabling the right diagnosis and care at the patient’s first appointment
Three Finnish biotech companies – Abacus Diagnostica, Kaivogen and Labrox – are joining forces to form an international frontrunner in vitro diagnostics. The new company will provide the global market with a unique total solution for point-of-care testing, including diagnostics for infectious diseases and cancers. It brings together some of the world’s leading instrumentation and biochemical know-how, and it will offer healthcare providers and patients faster, easier, and more cost-effective diagnostics. The transaction is to be completed in October. The name of the company will be decided during this autumn.
The three growth companies have years of experience in diagnostics: Abacus Diagnostica is a frontrunner in molecular testing and rapid PCR tests, Kaivogen specializes in immunoassays and antibody tests, and Labrox is an innovative developer of laboratory instruments.
Press release here.